A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation
Abstract Human antigen R (HuR) is a Swim ubiquitously expressed RNA-binding protein, which functions as an RNA regulator.Overexpression of HuR correlates with high grade tumours and poor patient prognosis, implicating it as an attractive therapeutic target.However, an effective small molecule antagonist to HuR for clinical use remains elusive.Here,